Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist

Taisuke Ezaki, Takeo Kosaka, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The efficacy of switching from a GnRH agonist to a GnRH antagonist for prostate cancer patients resistant to treatment with the GnRH agonist has not been fully characterized yet. We aimed to evaluate the efficacy of the switch to a GnRH antagonist in patients with PSA failure after hormonal therapy with a GnRH agonist. Methods: We retrospectively examined 18 patients with prostate cancer who received androgen-deprivation therapy and who were treated with a GnRH antagonist (degarelix) after they showed an elevated PSA while on GnRH agonist therapy. We evaluated the characteristics of the patients and analyzed some clinical factors for their potential association with the patient response to the switch. Results: The median PSA at the switch was 7.9 (0.37-1709) ng/ml, and the median testosterone level was 0.17 (<0.08-0.81) ng/ml. Three months after the switch, the median PSA level was 11.3 (0.22-2636) ng/ml, and the median testosterone level was 0.14 (<0.08-0.23) ng/ml. The PSA decreased in six patients (33.3 %) 1 month after the switch, and in three of them it decreased by more than 50 % by 3 months after the switch. Univariate analyses revealed that the lower number of prior treatment lines for prostate cancer before the switch was associated with a favorable decrease in PSA. Conclusions: Switching from GnRH agonist to GnRH antagonist therapy was effective for some prostate cancer patients with PSA failure. The small number of prior treatment lines for prostate cancer before the switch was significantly associated with a good PSA response.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume76
Issue number2
DOIs
Publication statusPublished - 2015 Jun 9

Fingerprint

Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Switches
Therapeutics
Testosterone
Androgens

Keywords

  • Androgen-deprivation therapy
  • GnRH antagonist
  • Prostate cancer
  • PSA failure

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist. / Ezaki, Taisuke; Kosaka, Takeo; Mizuno, Ryuichi; Shinojima, Toshiaki; Kikuchi, Eiji; Miyajima, Akira; Oya, Mototsugu.

In: Cancer Chemotherapy and Pharmacology, Vol. 76, No. 2, 09.06.2015, p. 301-306.

Research output: Contribution to journalArticle

@article{241a3e039baf40dea41341f4c26d6029,
title = "Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist",
abstract = "Purpose: The efficacy of switching from a GnRH agonist to a GnRH antagonist for prostate cancer patients resistant to treatment with the GnRH agonist has not been fully characterized yet. We aimed to evaluate the efficacy of the switch to a GnRH antagonist in patients with PSA failure after hormonal therapy with a GnRH agonist. Methods: We retrospectively examined 18 patients with prostate cancer who received androgen-deprivation therapy and who were treated with a GnRH antagonist (degarelix) after they showed an elevated PSA while on GnRH agonist therapy. We evaluated the characteristics of the patients and analyzed some clinical factors for their potential association with the patient response to the switch. Results: The median PSA at the switch was 7.9 (0.37-1709) ng/ml, and the median testosterone level was 0.17 (<0.08-0.81) ng/ml. Three months after the switch, the median PSA level was 11.3 (0.22-2636) ng/ml, and the median testosterone level was 0.14 (<0.08-0.23) ng/ml. The PSA decreased in six patients (33.3 {\%}) 1 month after the switch, and in three of them it decreased by more than 50 {\%} by 3 months after the switch. Univariate analyses revealed that the lower number of prior treatment lines for prostate cancer before the switch was associated with a favorable decrease in PSA. Conclusions: Switching from GnRH agonist to GnRH antagonist therapy was effective for some prostate cancer patients with PSA failure. The small number of prior treatment lines for prostate cancer before the switch was significantly associated with a good PSA response.",
keywords = "Androgen-deprivation therapy, GnRH antagonist, Prostate cancer, PSA failure",
author = "Taisuke Ezaki and Takeo Kosaka and Ryuichi Mizuno and Toshiaki Shinojima and Eiji Kikuchi and Akira Miyajima and Mototsugu Oya",
year = "2015",
month = "6",
day = "9",
doi = "10.1007/s00280-015-2798-4",
language = "English",
volume = "76",
pages = "301--306",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist

AU - Ezaki, Taisuke

AU - Kosaka, Takeo

AU - Mizuno, Ryuichi

AU - Shinojima, Toshiaki

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2015/6/9

Y1 - 2015/6/9

N2 - Purpose: The efficacy of switching from a GnRH agonist to a GnRH antagonist for prostate cancer patients resistant to treatment with the GnRH agonist has not been fully characterized yet. We aimed to evaluate the efficacy of the switch to a GnRH antagonist in patients with PSA failure after hormonal therapy with a GnRH agonist. Methods: We retrospectively examined 18 patients with prostate cancer who received androgen-deprivation therapy and who were treated with a GnRH antagonist (degarelix) after they showed an elevated PSA while on GnRH agonist therapy. We evaluated the characteristics of the patients and analyzed some clinical factors for their potential association with the patient response to the switch. Results: The median PSA at the switch was 7.9 (0.37-1709) ng/ml, and the median testosterone level was 0.17 (<0.08-0.81) ng/ml. Three months after the switch, the median PSA level was 11.3 (0.22-2636) ng/ml, and the median testosterone level was 0.14 (<0.08-0.23) ng/ml. The PSA decreased in six patients (33.3 %) 1 month after the switch, and in three of them it decreased by more than 50 % by 3 months after the switch. Univariate analyses revealed that the lower number of prior treatment lines for prostate cancer before the switch was associated with a favorable decrease in PSA. Conclusions: Switching from GnRH agonist to GnRH antagonist therapy was effective for some prostate cancer patients with PSA failure. The small number of prior treatment lines for prostate cancer before the switch was significantly associated with a good PSA response.

AB - Purpose: The efficacy of switching from a GnRH agonist to a GnRH antagonist for prostate cancer patients resistant to treatment with the GnRH agonist has not been fully characterized yet. We aimed to evaluate the efficacy of the switch to a GnRH antagonist in patients with PSA failure after hormonal therapy with a GnRH agonist. Methods: We retrospectively examined 18 patients with prostate cancer who received androgen-deprivation therapy and who were treated with a GnRH antagonist (degarelix) after they showed an elevated PSA while on GnRH agonist therapy. We evaluated the characteristics of the patients and analyzed some clinical factors for their potential association with the patient response to the switch. Results: The median PSA at the switch was 7.9 (0.37-1709) ng/ml, and the median testosterone level was 0.17 (<0.08-0.81) ng/ml. Three months after the switch, the median PSA level was 11.3 (0.22-2636) ng/ml, and the median testosterone level was 0.14 (<0.08-0.23) ng/ml. The PSA decreased in six patients (33.3 %) 1 month after the switch, and in three of them it decreased by more than 50 % by 3 months after the switch. Univariate analyses revealed that the lower number of prior treatment lines for prostate cancer before the switch was associated with a favorable decrease in PSA. Conclusions: Switching from GnRH agonist to GnRH antagonist therapy was effective for some prostate cancer patients with PSA failure. The small number of prior treatment lines for prostate cancer before the switch was significantly associated with a good PSA response.

KW - Androgen-deprivation therapy

KW - GnRH antagonist

KW - Prostate cancer

KW - PSA failure

UR - http://www.scopus.com/inward/record.url?scp=84938203900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938203900&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2798-4

DO - 10.1007/s00280-015-2798-4

M3 - Article

VL - 76

SP - 301

EP - 306

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -